GO29781

GO29781

An open-label, multicenter, phase I/IB trial evaluating the safety and pharmacokinetics of escalating doses of BTCT4465A as a single agent and combined with atezolizumab in patients with relapsed or refractory b-cell non-hodgkin’s lymphoma and chronic lymphocytic leukemia

Disease:

Follicular lymphoma, diffuse large B-cell lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, marginal zone lymphoma, mantle cell lymphoma, transformed indolent lymphoma

Summary:

This is a phase I study of the drug mosentuzumab (BTCT4465A) in patients with B-cell lymphoma or chronic lymphocytic leukemia that has returned after previous treatment. The medicine is given by intravenous infusion every 3 weeks. It works by activating your own immune system to attack and destroy lymphoma/leukaemia cells.

Eligibility:

Include, but not limited to, the following:

• Age >18
• A diagnosis of B-cell lymphoma, multiple myeloma or acute myeloid leukaemia which has continued to grow (refractory) or returned (relapsed) after previous treatment
• History of autoimmune disease
• History of brain involvement by lymphoma or active neurological problem (e.g. stroke, seizures within 2 years)

Contact person:

Lewis Edwards

Email ledwards@linear.org.au

Phone 6382 5125

Principal Investigator:

Dr Chan Cheah

Sponsor:

Genentech

Phase:

I/Ib

Protocol Number:

GO29781

Trial Registration Number:

Clinical Trials.gov

ANZ Clinical Trial Registry